Oncology

#AbbVie #Antibody drug conjugate (ADC) #MHRA #Oncology #Ovarian cancer

Elahere gets UK approval in platinum-resistant ovarian cancer

Elahere (mirvetuximab soravtansine) has become the first folate receptor-alpha (FRα) targeted antibody-drug conjugate (ADC) licensed in the UK for the treatment of adults with platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.  It is approved in patients who have received one to three prior systemic treatment… Read More

#News #Regulatory

Non-small cell lung cancer
#BeOne Medicines #CHMP #European Medicines Agency #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

Positive CHMP opinion for Tevimbra in neoadjuvant/adjuvant NSCLC

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Tevimbra (tislelizumab) for resectable non-small cell lung cancer (NSCLC).  It is recommended in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for adult patients at… Read More

#News #Regulatory

European Commission
#Autolus #CAR-T #Cell therapy #European Commission #Leukaemia #Oncology

Autolus Therapeutics’ CAR-T therapy gets EU green light

The European Commission (EC) has granted marketing authorisation for Aucatzyl (obecabtagene autoleucel or ‘obe-cel’) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL).  The EC approval was based on the results of the FELIX study, an open-label, multi centre, single arm… Read More

#News #Regulatory

Diffuse large B-cell lymphoma
#Artificial intelligence (AI) #Lantern Pharma #Lymphoma #Oncology #Orphan drugs #Phase I trial

Complete response in heavily pre-treated lymphoma patient

A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284.  Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More

#Cancer Research #Editor's Choice #News

Cancer cells
#Breast cancer #European Commission #Oncology #Roche

EC approves Roche’s Itovebi for breast cancer subtype

The European Commission has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It is approved following recurrence on or within 12 months of completing… Read More

#News #Regulatory

Colorectal cancer
#Cancer drug targets #Colorectal cancer #Oncology #University of Fukui

New molecular insights reveal potential colon cancer targets

New molecular insights into cancer stem cells have highlighted their potential as therapeutic targets.  In a recent study, researchers have revealed how transcription factors CDX1 and CDX2 suppress cancer cell stemness by blocking β-catenin’s ability to activate key genes like LGR5.   Their findings showed that… Read More

#Cancer Research #Editor's Choice #News

#Clinical trials #Next generation sequencing #Oncology #Sequencing

Bridging the clinical trials gap in cancer

Kathy Davy, President of Next-Generation Clinical Sequencing Division, Thermo Fisher Scientific, asks how clinical trials in cancer can be accelerated through the use of rapid next-generation sequencing (NGS) technology. Every cancer diagnosis marks the beginning of an urgent and often overwhelming journey for patients and their families. And in some… Read More

#Business & Investment #Cancer Research #Exclusive Content

#Dispatch Bio #Immunotherapy #Oncology #Solid tumours #Start-ups

Biotech aims to create universal solid tumour therapy

Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours.  Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment.   Dispatch’s Flare platform has been engineered to overcome these. Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Multiple myeloma
#FDA #GSK #Monoclonal antibodies #Myeloma #Oncology

FDA committee votes against Blenrep combinations for myeloma

The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile at GSK’s proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.   The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line… Read More

#News #Regulatory

Colon cancer
#China #Colorectal cancer #Monoclonal antibodies #Oncology #Pierre Fabre Laboratories

China approval for colorectal cancer combination treatment

The Chinese authorities have granted a marketing authorisation for Pierre Fabre Laboratories’ Braftovi, in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.  The approval is based on the Phase III BEACON CRC trial, which demonstrated a significant improvement in overall… Read More

#News #Regulatory

Leukaemia
#Ascentage Pharma #Blood cancer #China #Haematology #Oncology

First Bcl-2 inhibitor approved in China for CLL/SLL

Ascentage Pharma’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).  It is approved in patients who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. … Read More

#News #Regulatory

Monoclonal antibody
#AbbVie #Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Monoclonal antibodies #Oncology

AbbVie licenses trispecific antibody in billion-dollar contract

IGI Therapeutics, a wholly owned subsidiary of Ichnos Glenmark Innovation, and AbbVie have announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, for oncology and autoimmune diseases.  “Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by… Read More

#Business & Investment #News

Bladder
#AstraZeneca #Bladder cancer #European Commission #Monoclonal antibodies #Oncology

EU-approved bladder cancer therapy reduces death risk by 25%

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment.  According to the decision, this treatment should be followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery… Read More

#Cancer Research #News #Regulatory

Cancer cells
#Chemotherapy #Genetics / genomics #Oncology #University of Cambridge #Wellcome Sanger Institute

Chemotherapy finding could guide better treatments

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.  Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who… Read More

#Cancer Research #News

Bone cancer
#Immunotherapy #Oncology #OS Therapies #Osteosarcoma #Phase II trial #Rare disease

One-year event free survival reported at osteosarcoma conference

OS Therapies has shared positive clinical trial data updates from its Phase IIb clinical trial of immunotherapy candidate OST-HER2 in fully resected, lung metastatic osteosarcoma.  The data were presented by Principal Investigator Dr Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah… Read More

#Cancer Research #News

Patients receiving chemotherapy
#Biomarkers #Chemotherapy #Chemotherapy-resistance #Oncology #Tailor Bio

Biomarkers for chemo resistance unlock path to targeted therapies

Techbio Tailor Bio has published a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.  The study, carried out in collaboration with the University of Cambridge and the Spanish National Cancer… Read More

#Cancer Research #Editor's Choice #News